CortagenvsPinealon

Cortagen (Ala-Glu-Asp-Pro) is a synthetic tetrapeptide belonging to the Khavinson family of peptide bioregulators — short peptides proposed to regulate gene expression in a tissue-specific manner. The bioregulator hypothesis, developed by Professor Vladimir Khavinson over decades of research at the St. Petersburg Institute of Bioregulation and Gerontology, proposes that short peptides (2-4 amino acids) can penetrate cell membranes and nuclear envelopes, interact directly with DNA in a sequence-specific manner, and modulate transcription of tissue-relevant genes.

Cortagen is specifically designed to target neurons of the cerebral cortex. According to the Khavinson model, the AEDP tetrapeptide sequence has complementarity to specific DNA sequences in gene promoter regions active in cortical neurons. Upon binding to these regulatory elements, Cortagen is proposed to modulate chromatin structure and transcription factor access, influencing the expression of genes involved in neuronal function, synaptic transmission, antioxidant defense, and protein synthesis. The tissue specificity — cortex rather than other brain regions or body tissues — is attributed to the unique chromatin accessibility and transcription factor environment in cortical neurons that determines which genes are available for regulation.

Preclinical studies from Russian research programs have reported that Cortagen treatment improves cognitive function, enhances learning and memory, and provides neuroprotection in models of cerebral ischemia and age-related cognitive decline. The proposed mechanism involves restoration of age-related declines in protein synthesis in cortical neurons, enhancement of antioxidant enzyme expression (SOD, catalase, GPx), and improved synaptic function through upregulation of synaptophysin and other synaptic proteins. It should be noted that the peptide bioregulator field remains controversial in Western pharmacology — while the Russian research program is extensive, the proposed direct DNA-binding mechanism has not been independently validated through the standard molecular biology methods expected in Western peer-reviewed literature.

Pinealon is a short tripeptide (Glu-Asp-Arg) belonging to the Khavinson family of peptide bioregulators — small peptides hypothesised to regulate gene expression in tissue-specific ways by binding directly to DNA promoter regions. Pinealon is the brain- and pineal-gland-targeted member of this family, designed to penetrate cells and the nuclear membrane to interact with promoter sequences of genes involved in neuronal function and circadian regulation.

Proposed mechanisms include modulation of melatonin synthesis pathways (via effects on pineal gland function), upregulation of antioxidant defence enzymes in neurons, and protection against oxidative stress from age-related accumulation of reactive oxygen species. Russian preclinical studies have reported pinealon-induced increases in expression of genes involved in serotonin and melatonin metabolism, neurotrophic factor signalling, and antioxidant capacity, alongside protective effects against neurotoxin-induced neuronal damage in animal models.

The extremely short plasma half-life (around 30 minutes) is a feature shared with all Khavinson tripeptides — the proposed model is that the peptides act as transient signalling molecules that trigger longer-lasting changes in gene expression, with effects persisting well beyond plasma clearance. This model would explain the use of pulse-dosing protocols (10-30 day courses repeated periodically) rather than continuous administration. Importantly, almost all published efficacy data comes from Russian research groups associated with the original Khavinson laboratory, and the bioregulator framework has not been independently validated in Western clinical settings. Mechanistic claims should be treated as preliminary, and clinical use remains largely anecdotal outside Russia.